Castle Biosciences, Inc.NASDAQ: CSTL

Castle Biosciences to Participate in Upcoming Investor Conferences

· Issued by Castle Biosciences, Inc. via PR Newswire

Summary by 6ix AI

Castle Biosciences, a company that makes diagnostic tests to guide patient care, says its executive management is scheduled to present a company overview at the Stephens Annual Investment Conference on Wednesday, November 18, 2026, at 12:30 p.m. Central time.

Key details

  • A live audio webcast of the presentation will be available on Castle Biosciences' investor website, with a replay available after the live broadcast ends.
  • Castle will also be available for one-on-one investor meetings during the Jefferies Global Healthcare Conference, held November 16 to 19, 2026; meetings may be requested only through Jefferies Financial Group.

6ix AI wrote this summary from the release below and checked it against the release.

FRIENDSWOOD, Texas, Oct. 28, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the Stephens Annual Investment Conference on Wednesday, Nov. 18, 2026, at 12:30 p.m. Central time.

A live audio webcast of the Company's presentation will be available by visiting Castle Biosciences' website at ir.castlebiosciences.com/events-presentations/. A replay of the webcast will be available following the conclusion of the live broadcast.

Castle will also be available for one-on-one investor meetings during the Jefferies Global Healthcare Conference, being held Nov. 16-19, 2026. Meetings may be requested exclusively through Jefferies Financial Group.

About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. With a primary focus in dermatologic and gastroenterological disease, we develop personalized, clinically actionable solutions that help improve disease management and patient outcomes.

We put people first—empowering patients and clinicians and informing care decisions through rigorous science and advanced molecular tests that support more confident treatment planning. To learn more, visit www.CastleBiosciences.com and connect with us on LinkedIn, Instagram, Facebook and X.

DecisionDx-Melanoma, DecisionDx-CMSeq, i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, AdvanceAD-Tx, TissueCypher, Esopredict, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.

Investor Contact:
Camilla Zuckero
[email protected]

Media Contact:
Allison Marshall
[email protected]

SOURCE Castle Biosciences, Inc.

View original source (PR Newswire)Castle Biosciences, Inc. on 6ix

Story so far

Earlier from Castle Biosciences

Later from Castle Biosciences

All Castle Biosciences news releases